CureVac’s Covid Vaccine Performed Badly in Trial, In Part Due to Variants

A preliminary analysis estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.A preliminary analysis estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.internal-essential, Vaccination and Immunization, Coronavirus (2019-nCoV), CureVac GmbH, Clinical TrialsRead More